Biogen-Idec and Elan just told you that disability progression as measured by EDSS scores showed Tysabri patients did far better than placebo group. The companies said they would release full data at AAN in April.
more mysterious people with information that continues to be contradicted by released data, by anecdotes told by real patients here and on other MS boards, and by the companies themselves.
MeadowStream wrote:ptwo, that extremely low incidence of side effects is very interesting and clearly a differentiator (along with twice the efficacy of alternative treatments and once-per-month dosing) from alternatives. Thanks for pointing out another thing to look forward to.
Do sufferers always have to go up the scale to the very top?
Until the drugs companies can get to grips with neuro-protection I don't imagine we will see much improvement in the future of sufferers.
However, given this, why can't they fast track this treatment - for those willing to take the risk. I know that safety and risks need to be considered, but when this is set alongside a chance that severe disability might be reduced or deferred it must be a risk worth taking.
I've been wanting to raise an issue for a while, but this might be the right time. Would any members be interested in a forum about quality of life issues as the disease progresses (quite frankly about when one might call it a day). It's not a nice issue, but then this is not a nice disease. Perhaps Aaron could advise if this would be acceptable - only for those who wished to participate.
Users browsing this forum: No registered users